Does Rallies show Form 4 insider transactions for KROS?

Yes. Rallies tracks KROS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KROS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KROS. It does not provide personalized investment advice.

KROS (Keros Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Keros Therapeutics, Inc. Common Stock (KROS) is a publicly traded Healthcare sector company. As of May 21, 2026, KROS trades at $10.98 with a market cap of $201.09M and a P/E ratio of 4.57. KROS moved +11.10% today. Year to date, KROS is -38.73%; over the trailing twelve months it is -22.35%. Its 52-week range spans $9.12 to $72.37. Analyst consensus is buy with an average price target of $21.20. Rallies surfaces KROS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KROS stock inside the company?

Recent KROS insider activity includes BIENAIME JEAN JACQUES bought 1.00K, BIENAIME JEAN JACQUES bought 2.00K, Seehra Jasbir sold 7.01K, Lerner Lorena Raquel sold 3.87K, and Cho Esther sold 4.75K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KROS Key Metrics

Key financial metrics for KROS
Metric	Value
Price	$10.98
Market Cap	$201.09M
P/E Ratio	4.57
EPS	$2.34
Dividend Yield	0.00%
52-Week High	$72.37
52-Week Low	$9.12
Volume	0
Avg Volume	0
Revenue (TTM)	$243.86M
Net Income	$87.01M
Gross Margin	0.00%

Recent KROS Insider Trades

BIENAIME JEAN JACQUES bought 1.00K (~$11.70K) on Apr 15, 2026.
BIENAIME JEAN JACQUES bought 2.00K (~$22.42K) on Mar 9, 2026.
Seehra Jasbir sold 7.01K (~$113.43K) on Feb 19, 2026.
Lerner Lorena Raquel sold 3.87K (~$63.32K) on Feb 18, 2026.
Cho Esther sold 4.75K (~$77.58K) on Feb 18, 2026.

Latest KROS News

Keros Therapeutics Reports $23.7M Q1 Loss, R&D Costs Fall 67% on Takeda Transition — May 14, 2026
Keros Therapeutics Launches Phase 2 ALS Trial Design with Healey ALS MyMatch — Mar 9, 2026
Keros Therapeutics Triggers $10M Milestone with Phase III RENEW Trial Start — Mar 5, 2026
Keros to Launch DMD Trial and Pursue ALS Phase II, Backed by $200M Takeda Deal — Feb 28, 2026
Keros Therapeutics Cuts 45% Staff, Shelves Cibotercept to Fund KER-065 Phase II Trial — Jan 16, 2026

KROS Analyst Consensus

8 analysts cover KROS: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.20.

Common questions about KROS

Who is trading KROS stock inside the company?: Recent KROS insider activity includes BIENAIME JEAN JACQUES bought 1.00K, BIENAIME JEAN JACQUES bought 2.00K, Seehra Jasbir sold 7.01K, Lerner Lorena Raquel sold 3.87K, and Cho Esther sold 4.75K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KROS?: Yes. Rallies tracks KROS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KROS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KROS. It does not provide personalized investment advice.